The survival time of pancreatic cancer patients treated with chemotherapy after recurrence is shorter, usually less than 1 year, and the specific survival time depends on the size and location of the recurrent foci, the specific stage, the response to the treatment as well as the patient’s physical condition. Pancreatic cancer has the possibility of recurrence, and after recurrence, it is usually in the middle or late stage, and patients have usually lost the chance of surgical resection, and are often given chemotherapy, radiotherapy, immunotherapy, etc. to control the disease, and the prognosis is often poor. Studies have shown that in the combination of gemcitabine and erlotinib for the treatment of advanced pancreatic cancer, the objective response rate of patients was 14.4%, the disease control rate was 55.0%, the 1-year overall survival rate was 28.5%, the progression-free survival period was 2.63-9.60 months, and the overall survival period was 6-10 months. However, the prognosis after recurrence is very poor. It is recommended to go to a regular hospital to evaluate the condition, follow the doctor’s instructions to cooperate with the treatment, and choose the appropriate treatment plan to prolong the survival and improve the quality of life.